Literature DB >> 11900797

Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.

Benedict A Gomes1, Ji Shen, Kristi Stafford, Minesh Patel, Byron C Yoburn.   

Abstract

In the present study, the contribution of pertussis toxin (PTX)-sensitive G(i/o)-proteins to opioid tolerance and mu-opioid receptor down-regulation in the mouse were examined. Mice were injected once intracerebroventricularly and intrathecally with PTX (0.1 microg/site). Controls were treated with saline. On the 10th day following PTX treatment, continuous subcutaneous infusion of etorphine (150 or 200 microg/kg/day) or morphine (40 mg/kg/day+25 mg slow-release pellet) was begun. Control mice were implanted with inert placebo pellets. Pumps and pellets were removed 3 days later, and mice were tested for morphine analgesia or mu-opioid receptor density was determined in the whole brain, spinal cord, and midbrain. Both infusion doses of etorphine produced significant tolerance (ED50 shift=approximately 4-6-fold) and down-regulation of mu-opioid receptors (approximately 20-35%). Morphine treatment also produced significant tolerance (ED50 shift= approximately 5-8-fold), but no mu-opioid receptor down-regulation. PTX dramatically reduced the acute potency of morphine and blocked the further development of tolerance by both etorphine and morphine treatments. However, PTX had no effect on etorphine-induced mu-opioid receptor down-regulation in brain, cord, or midbrain. These results suggest that PTX-sensitive G-proteins have a minimal role in agonist-induced mu-opioid receptor density regulation in vivo, but are critical in mediating acute and chronic functional effects of opioids such as analgesia and tolerance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11900797     DOI: 10.1016/s0091-3057(01)00757-2

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

1.  Deciphering µ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells.

Authors:  Christian Doll; Florian Pöll; Kenneth Peuker; Anastasia Loktev; Laura Glück; Stefan Schulz
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Lack of Antinociceptive Cross-Tolerance With Co-Administration of Morphine and Fentanyl Into the Periaqueductal Gray of Male Sprague-Dawley Rats.

Authors:  Erin N Bobeck; Shauna M Schoo; Susan L Ingram; Michael M Morgan
Journal:  J Pain       Date:  2019-03-07       Impact factor: 5.820

3.  Biased antagonism of CXCR4 avoids antagonist tolerance.

Authors:  Ben Hitchinson; Jonathan M Eby; Xianlong Gao; Francois Guite-Vinet; Joshua J Ziarek; Hazem Abdelkarim; Youngshim Lee; Yukari Okamoto; Sojin Shikano; Matthias Majetschak; Nikolaus Heveker; Brian F Volkman; Nadya I Tarasova; Vadim Gaponenko
Journal:  Sci Signal       Date:  2018-10-16       Impact factor: 8.192

4.  mu-Opioid receptors: Ligand-dependent activation of potassium conductance, desensitization, and internalization.

Authors:  Veronica A Alvarez; Seksiri Arttamangkul; Vu Dang; Abdallah Salem; Jennifer L Whistler; Mark Von Zastrow; David K Grandy; John T Williams
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

Review 5.  Tolerance and withdrawal from prolonged opioid use in critically ill children.

Authors:  Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

Review 6.  Regulation of opioid receptor signalling: implications for the development of analgesic tolerance.

Authors:  Karim Nagi; Graciela Piñeyro
Journal:  Mol Brain       Date:  2011-06-13       Impact factor: 4.041

Review 7.  Opioid receptor desensitization: mechanisms and its link to tolerance.

Authors:  Stéphane Allouche; Florence Noble; Nicolas Marie
Journal:  Front Pharmacol       Date:  2014-12-18       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.